NEW YORK , Sept. 14, 2022 /PRNewswire/ -- Yuvo Health, a leading technology-enabled administrative and managed-care solution for community health centers, today announced a partnership with Primary Care Development Corporation (PCDC), a Community Development Financial Institution (CDFI) and national non-profit that aims to increase access to primary care and achieve health equity through community investment, capacity building, and policy initiatives. Together, they will provide Federally Qualified Health Centers (FQHCs) with access to a robust set of support services and new revenue streams through upside risk contracts. Additionally, FQHCs will be able to participate in Yuvo's independent physician association (IPA) and receive support services that are supplemented by PCDC's services.
"We're delighted to partner with PCDC, which has been providing the capital, advocacy, research, and expertise needed to build equity and excellence in primary care," said Cesar Herrera , CEO of Yuvo Health, which he co-founded in New York City with a fully BIPOC team. "Bringing fair, quality care to underserved communities is our greatest priority, and since PCDC works with several health centers across the country, joining forces with them fosters a great collaboration for us, especially in New York where they've been active for 30 years."
Recently, Yuvo Health and Fidelis Care , New York State's largest Medicaid managed care organization, announced the submission of a value-based payment (VBP) contract to the New York State Department of Health that supports the provision of quality, affordable care to historically marginalized and priority populations. Forging strategic partnerships to benefit communities is part of the company's rapidly scaling efforts since launching in January 2021 .
"We are excited to support FQHCs with training and customized strategies as they seek to expand revenue opportunities that will sustain the important services they provide in historically disinvested communities," said Isaac Kastenbaum , Vice President, Training & Technical Assistance, at PCDC. "We're pleased to partner with Yuvo Health, which shares our deep commitment to both FQHCs and expanding investment in primary care, overall."
In May 2022 , Yuvo Health announced four FQHCs that joined the company's independent provider association (IPA): Long Island Select Healthcare, Metro Community Health Centers, Joseph P. Addabbo Family Health Center, and Advantage Care Health Centers. Earlier this year, the company revealed a $7.3 million seed round of funding to expand its initial program in downstate New York and strengthen partnerships with FQHCs in the greater New York area and beyond.
Over the coming months, Yuvo Health will be developing customized programs to support the unique needs of their FQHC and community health center partnerships throughout the country, starting with New York . To learn more about Yuvo Health and their programs for community health centers, click here.
Launched in January 2021 , Yuvo Health was founded in New York City by a fully BIPOC team with the common goal of bringing fair, quality care to underserved communities. A team that shares first-hand experience of the impact quality health care can make, strive to instill more compassionate care within healthcare systems. Yuvo Health is continuously proving their innovation and reliability by providing an industry-leading product of administrative and managed-care contracting solutions to Federally Qualified Health Centers (FQHC). Yuvo aims to relieve administrative pressure from FQHCs to allow them to focus completely on providing quality care to communities in need. While continuing to serve the downstate New York market, Yuvo anticipates providing their services across New York , the Midwest and the Mid-Atlantic regions. For more information, please visit www.yuvohealth.com.
Founded in 1993, the Primary Care Development Corporation (PCDC) is a Community Development Financial Institution and nationally recognized nonprofit organization dedicated to expanding access to quality primary care, in order to improve the health of families and communities, lessen disparities, and reduce health care costs. PCDC offers training and technical assistance on providing health care services that are accessible, high-quality, and compassionate; affordable capital to renovate and expand community health centers so that services are offered in settings that promote efficiency, dignity, and respect; and advocacy to advance public policies that strengthen and sustain quality primary care. To date, PCDC has helped over 3,000 primary care practices improve delivery of care and leveraged over $1.3 billion in capital to enhance capacity in disinvested communities. For more information, please contact PCDC at info@pcdc.org or visit www.pcdc.org.
View original content:https://www.prnewswire.com/news-releases/yuvo-health-partners-with-primary-care-development-corporation-pcdc-to-expand-and-support-primary-care-access-in-marginalized-communities-301624052.html
UBS's Colin Bristow raised his rating on the stock to Buy from Neutral, saying Well Street's expectations for sales of Mounjaro are too low.
This drugmaker has earned two new drug approvals in as many months, but its success isn't reflected in its market valuation yet.
The exclusive licensing agreement with GSK will fund Spero's (SPRO) existing operations and extend its current cash runway beyond 2024.
Shares of Eli Lilly & Co. Inc. gained 2.5% in premarket trading on Thursday after UBS upgraded the stock to buy from neutral, saying Mounjaro, the company's newly approved Type 2 diabetes drug, could be "the biggest drug ever." UBS analysts predict peak sales of $25 billion if the therapy is also approved as a treatment for weight management in people with obesity. "Tirzepatide's robust efficacy in both obesity and [Type 2 diabetes] should drive sales into a range that we believe could see this
Eli Lilly is the IBD Stock Of The Day as investors watch the company's obesity and Alzheimer's drugs, which could help shares skyrocket.
The 'wrongful death' suit could usher in a new threat for abortion providers and women nationwide
Eli Lilly's blockbuster potential diabetes drug Mounjaro is "de-risked and transformative," an analyst said Thursday as he updated LLY stock.
Roche's (RHHBY) eye drug, Vabysmo and AstraZeneca's (AZN) asthma drug Tezspire get approval in Europe. The FDA approves expanded use of Lilly's (LLY) cancer drug, Retevmo.
It is safe to get the newly formulated COVID-19 booster shot and the flu shot at the same time. SDI Productions/ E+ via Getty ImagesAt this point in the COVID-19 pandemic, nearly everyone has experienced the panic and uncertainty that come with having mild COVID-like symptoms – such as a cough and sore throat – only to test negative day after day. With cold and flu season just around the corner, that state of frustrating uncertainty is likely to strike most of us again. Both COVID-19 and the flu
From biotech to managed care, companies are tackling new challenges in science and business. Our healthcare roundtable experts pick 12 stocks that could win.
Less than five months after discouraging conversations with the U.S. Food and Drug Administration led Spero Therapeutics Inc. to pause work on a drug and lay off 110 people, the company is licensing that same drug to GSK plc for up to $291 million.
A potentially disruptive business model is finding its legs in the post-pandemic healthcare landscape.
Following the release of scathing briefing documents, FDA's Oncologic Drugs Advisory Committee voted 9-4 against Spectrum Pharmaceuticals Inc's (NASDAQ: SPPI) poziotinib benefit-risk profile. FDA presenters said significant issues with the poziotinib application include its insufficient efficacy in the pivotal trial, the high rate of toxicity, inadequate dose optimization, and the delayed confirmation of benefit, as the company is yet to enroll patients in its proposed confirmatory study. Futili
Ionis stock tumbled Friday after partner AstraZeneca decided against sending their high cholesterol treatment into Phase 3 testing.
Fox New’s Peter Doocy and White House Press Secretary Jean-Pierre had a tense moment regarding his question on President Biden’s stance on abortion restrictions. KJP: “As you know, as you know Kevin McCarthy put out the GOP agenda.”
“Whenever you lose a pregnancy it is always cautious optimism when you are pregnant again,” Legend says.
The photo was released the day of the premiere of the new season of "The Kardashians."
Shares of Bristol Myers Squibb (NYSE: BMY) were bouncing 3.4% higher as of 3:31 p.m. ET on Thursday after slipping a little earlier this week. Instead, today's move appeared to be the result of investors seeking relatively safe stocks as the Nasdaq Composite index and Russell 2000 small-cap index fell. Bristol Myers Squibb has seemed to be sort of a safe haven for investors throughout much of 2022.
In some instances, cancer patients who were denied treatment because of their pregnancies were also unable to receive abortions, an affidavit alleges
Evaxion (EVAX) enrolls the first patient in the phase IIb study evaluating its cancer therapy, EVX-01 in combination with Keytruda, for treating melanoma.